Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

TheMotleyFool

0 0

Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. The company also recently announced positive results for the therapy in treating severe COVID-19. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.

Source Fool.com

Like: 0

AZN

Share